v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses    
Research and development $ (4,747) $ (3,930)
General and administrative (4,019) (7,272)
Loss from operations (8,766) (11,202)
Other income/(expenses)    
Interest income 327 659
Interest expense (20) (180)
Changes in the fair value of warrants 17 416
Foreign currency transaction gain/(loss), net 1,628 (2,765)
Benefit from research and development tax credit 95 185
Net loss before income tax (6,719) (12,887)
Income tax benefit 0 0
Net loss $ (6,719) $ (12,887)
Loss per share - basic $ (0.01) $ (0.02)
Loss per share - diluted $ (0.01) $ (0.02)
Weighted average shares outstanding - basic 801,805,570 784,279,387
Weighted average shares outstanding - diluted 801,805,570 784,279,387
Net loss $ (6,719) $ (12,887)
Other comprehensive (loss)/income - Foreign currency translation adjustments, net of tax (1,748) 3,559
Total comprehensive loss $ (8,467) $ (9,328)